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Abstract: DNA hypermethylation is an important epigenetic mechanism for gene expression inacti-
vation in head and neck cancer (HNC). Saliva has emerged as a novel liquid biopsy representing a
potential source of biomarkers. We performed a comprehensive meta-analysis to evaluate the overall
diagnostic accuracy of salivary DNA methylation for detecting HNC. PubMed EMBASE, Web of
Science, LILACS, and the Cochrane Library were searched. Study quality was assessed by the Quality
Assessment for Studies of Diagnostic Accuracy-2, and sensitivity, specificity, positive likelihood
ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (dOR), and their corresponding
95% confidence intervals (CIs) were calculated using a bivariate random-effect meta-analysis model.
Meta-regression and subgroup analyses were performed to assess heterogeneity. Eighty-four study
units from 18 articles with 8368 subjects were included. The pooled sensitivity and specificity of
salivary DNA methylation were 0.39 and 0.87, respectively, while PLR and NLR were 3.68 and
0.63, respectively. The overall area under the curve (AUC) was 0.81 and the dOR was 8.34. The
combination of methylated genes showed higher diagnostic accuracy (AUC, 0.92 and dOR, 36.97)
than individual gene analysis (AUC, 0.77 and dOR, 6.02). These findings provide evidence regarding
the potential clinical application of salivary DNA methylation for HNC diagnosis.
Keywords: DNA methylation; epigenetics; head and neck cancer; saliva; biomarkers; liquid biopsy;
meta-analysis
1. Introduction
Head and neck cancer (HNC) comprises a heterogenous group of epithelial malig-
nancies arising from mucosal linings of the oral cavity, oropharynx, larynx, and hypophar-
ynx. According to data from the World Health Organization’s GLOBOCAN network,
HNC is highly prevalent worldwide, accounting for an estimated 890,000 new cases and
450,000 deaths in 2018 [1]. Despite improvements in diagnosis and therapeutic strategies,
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the 5-year survival rate for HNC has remained around 50% for the last decade. Unfortu-
nately, HNC patients are frequently diagnosed in advanced stages involving a high risk
of locoregional recurrence and distant metastasis [2,3]. Therefore, it is necessary to iden-
tify new biomarkers for diagnosis and prognosis to allow early detection and improved
overall survival. HNC arises through multistep carcinogenic pathways as a result of cu-
mulative genetic and epigenetic aberrations resulting from risk factors including alcohol
and tobacco consumption, human papillomavirus infection, chronic inflammation, and
genetic predisposition, and leading to reduced tumor suppressor gene function as well as
oncogene activation [2,4]. In recent years, accumulating scientific evidence has highlighted
the important role in tumorigenesis of epigenetic mechanisms, which represent a cancer
hallmark [5,6]. Epigenetic alterations such as DNA methylation, histone covalent modifica-
tions, chromatin remodeling, and non-coding RNAs have been implicated in the landscape
of phenotypical changes occurring in a wide variety of malignancies, including HNC [7].
DNA hypermethylation has been shown to be an important epigenetic mechanism for gene
expression inactivation. The hypermethylation of cytosine–phosphodiester bond–guanine
(CpG) islands within promoter regions plays an important role in carcinogenesis through
the transcriptional silencing of different tumor suppressor genes or dysfunction in DNA
repair genes [7,8]. Several studies have focused on the identification of aberrant promoter
methylation patterns in HNC tissue and liquid biopsies [9,10]. Moreover, a number of in-
vestigations have detected promoter hypermethylation in various genes using saliva from
HNC patients [10–12]. Therefore, salivary DNA hypermethylation represents a promising
biomarker for non-invasively diagnosing HNC.
DNA methylation is a heritable and stable epigenetic mechanism implicated in the
regulation of gene expression that plays an important role during normal development, reg-
ulating X chromosome inactivation, genomic imprinting, and preventing the transcription
of DNA repetitive sequences, inserted viral sequences, and transposons [8,13]. DNA methy-
lation is characterized by the covalent addition of a methyl group to the 5’-position of the
pyrimidine ring of cytosines by DNA methyltransferases, giving rise to 5-methylcytosine.
This enzymatic process occurs predominantly within CpG dinucleotides which are concen-
trated at CpG-rich DNA stretches named CpG islands (CGIs), which overlap the promoter
region of 60–70% of protein-coding genes [14]. In the human genome, approximately 80%
of CpG dinucleotides are heavily methylated whereas CGIs in gene promoters are mostly
unmethylated, allowing active gene transcription [13]. Dysregulation of DNA methylation
has been found to be involved in several diseases, representing an early epigenetic event in
carcinogenesis. These alterations of normal DNA methylation patterns in cancer have been
characterized as global hypomethylation and gene-specific hypermethylation. The global
hypomethylation of repetitive sequences and transposable elements within the genome
induces genomic instability and mutagenesis. In this line, the loss of DNA methylation may
also activate latent viral sequences, promoting carcinogenesis. By contrast, in addition to
global hypomethylation, aberrant promoter hypermethylation can drive the inactivation of
key tumor suppressor genes, which are unmethylated in non-malignant tissues [15]. In this
sense, although silencing by DNA hypermethylation of some genes is common in many
types of tumors, the methylation profile of gene promoters is different for each human can-
cer, allowing the identification of cancer-specific hypermethylation patterns [16]. Although
tissue biopsy of the primary tumor or metastatic lesions remains the gold standard method
for diagnosis, DNA methylation biomarkers can be assessed in different liquid biopsies,
representing a non-invasive alternative for early cancer detection [10,17,18].
Recently, saliva has emerged as an attractive liquid biopsy for genomic and epige-
nomic analysis. Saliva-based liquid biopsy is a fast, reliable, cost-effective, and non-invasive
approach to analyze epigenetic alterations involved in the onset and course of the dis-
ease. Some researchers have found comparable methylation profiles between saliva and
tissue, representing a non-invasive alternative for epigenomic profiling [19,20]. Addition-
ally, although similar methylation DNA patterns have been reported between saliva and
blood [21,22], methylation differences between both biofluids can be identified due to
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tumor shedding and tissue-specific methylation [23,24]. Focusing on promoter hyperme-
thylation, a number of investigations have detected various methylated genes in saliva,
representing a promising biomarker for non-invasive HNC detection [10–12].
The purpose of this systematic review and meta-analysis was to summarize the results
of published clinical studies to assess the overall diagnostic accuracy of salivary DNA
hypermethylation for discriminating HNC.
2. Materials and Methods
2.1. Protocol and Registration
This study was conducted according to Preferred Reporting Items for Systematic Re-
views and Meta-analysis (PRISMA) guidelines [25], and the protocol was registered with the
International Prospective Register of Systematic Reviews (reference No. CRD42020199114).
2.2. Search Strategy and Study Selection
The systematic literature search of eligible articles published up to 27 August 2020
was carried out without language restrictions using PubMed, EMBASE, Web of Science,
LILACS, and the Cochrane Library. The search strategy was based on the following
combinations of keywords and medical subject headings: (methylation OR hypermethyla-
tion OR epigenomics) AND (saliva OR oral rinse OR mouthwash) AND (head and neck
cancer OR head and neck neoplasm OR head and neck carcinoma OR head and neck
squamous cell carcinoma OR HNSCC OR oral cancer OR pharyngeal cancer OR laryngeal
cancer). Studies were screened based on title and abstract, and eligible manuscripts were
retrieved for full-text review. In addition, reference lists from each original and review
article were searched manually in order to find further relevant studies. The literature
search was performed independently by two investigators (ORG and MMSC), and dis-
agreements during the selection process were resolved by consensus. The studies selected
by means of the search strategy and other references were managed using RefWorks
software (https://www.refworks.com/content/path_learn/faqs.asp, accessed 28 October
2020), and duplicate items were removed using the associated tools.
2.3. Selection Criteria
The inclusion criteria were as follows: (1) studies that evaluated the diagnostic accu-
racy of gene promoter hypermethylation in saliva samples from HNC patients; (2) inclusion
of a control group consisting of healthy controls; (3) sufficient data for generating a two-by-
two (2 × 2) contingency table containing true positive (TP), false positive (FP), true negative
(TN), and false negative (FN) values. The exclusion criteria were as follows: (1) reviews,
letters, personal opinions, book chapters, case reports, conference abstracts, and meetings;
(2) duplicate publications; (3) in vitro and in vivo animal experiments.
2.4. Data Extraction
All eligible studies were assessed independently by two investigators (ORG and
MMSC) and data were extracted using a pre-established form designed on a Microsoft
Excel spreadsheet (Microsoft Corp. Redmond, WA, USA). Any disagreement among
reviewers was resolved by consensus. The following information was extracted from each
study: name of first author, year of publication, country, anatomic tumor location, number
of cases and controls, positive methylated cases, positive methylated controls, method
for DNA methylation detection, type of saliva sample (saliva or oral rinse), methylated
gene names, and statistical analysis outcomes, including diagnostic accuracy and cut-
off values. If the required data were incomplete, attempts were made to contact the
authors to obtain the missing information. We defined “study unit” as the analysis of
a relationship between gene promoter hypermethylation and HNC. Therefore, a single
publication could potentially include more than one study unit as a result of reporting
promoter hypermethylation for multiple genes.
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2.5. Quality Assessment of Individual Studies
Following Healthcare Research and Quality Agency recommendations, two indepen-
dent researchers (ADL and LMR) applied the Quality Assessment of Diagnostic Accuracy
Studies-2 checklist (QUADAS-2) [26]. Any discrepancies were resolved by a third reviewer
(MMSC). The QUADAS-2 checklist assesses study quality by analyzing four key domains:
(1) patient selection, (2) index tests, (3) reference tests, and (4) flow and times. Risk of bias
and applicability concerns for each domain were assessed as “low”, “high”, or “unclear”.
One point was assigned to each item assessed as “low”. Thus, articles were grouped into the
following quality categories based on their cumulative score: “high” quality (6–7 points),
“moderate” quality (4–5 points), and “low” quality (0–3 points).
2.6. Statistical Analysis
MetaDiSc software (v.1.4) [27], free R software (v.3.4.4; https://www.r-project.org,
accessed 30 November 2020), and STATA (v.14.0; https://www.stata.com, accessed 30
November 2020) were used to carry out statistical analysis. The numbers of TP, FP, FN, and
TN in each study unit in the diagnostic meta-analysis were extracted to calculate pooled
sensitivity [TP/(TP + FN)], specificity [TN/(TN + FP)], positive likelihood ratio (PLR) [(sen-
sitivity/(1 − sensitivity)], negative likelihood ratio (NLR), [(1 − specificity)/specificity)],
diagnostic odds ratio (dOR), and their corresponding 95% confidence intervals (CIs) using
a bivariate random or fixed effect meta-analysis model. The pooled diagnostic perfor-
mance of salivary DNA promoter hypermethylation for HNC detection was determined
by plotting the summary receiver operator characteristic (SROC) curve and calculating
the area under the SROC curve (AUC). Heterogeneity analysis was used to identify fac-
tors influencing accuracy indicators and the statistical model applied [27]. Spearman’s
correlation analysis and ROC plane plots were used to assess heterogeneity due to the
threshold effect. Cochran’s Q statistic test-based chi-squared test and I2 statistics were used
to assess non-threshold heterogeneity. When I2 > 50% and/or p < 0.05 for the Cochran’s Q
test, heterogeneity was considered to be significant. The DerSimonian and Laird random
effects model was applied when heterogeneity was significant; otherwise, we applied the
Mantel–Haenszel fixed effects model. Potential sources of non-threshold heterogeneity
were explored by meta-regression and subgroup analyses. In addition, the predictive value
of post-salivary DNA promoter hypermethylation for HNC diagnosis was evaluated by
Fagan’s nomogram. Post-test probability was calculated using Bayes theorem under the
assumption of prior probabilities of 25%, 50%, and 75%, respectively [28]. Deeks’ funnel
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in Figure 1. A total of 576 studies were identified based on the search strategy across the
five electronic databases, which was reduced to 470 after removing duplicates. After title
and abstract review, 27 articles were submitted for full-text reading, of which nine were
excluded for the following reasons: non-independent cancer group (two articles); reviews,
letters, personal opinions, book chapters, case reports, conference abstracts, and meetings
(three articles); absence of a healthy control group (one article); saliva enriched with brush
oral cytology (two articles); and insufficient information for meta-analysis (one article). In
the end, 18 articles met the inclusion criteria for final analysis [10–12,30–44].
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3.2. Characteristics of Included Studies 
The characteristics of the included studies are shown in Table 1. The 18 articles com-
prised a total of 84 study units, including 4758 HNC patients and 3605 healthy individuals 
(the sample size ranged from 13 [31] to 210 [41]). All articles were published between 2001 
and 2020, and studies were conducted in the following geographical regions: the United 
States (5), Australia (3), Thailand (2), Japan (2), France (1), Brazil (1), India (1), Taiwan (1), 
Colombia (1), and Italy (1). Saliva samples included oral rinses (12) and whole saliva (6). 
Salivary DNA methylation was detected by different methods, including methylation-
specific polymerase chain reaction (MSP) (11) and quantitative MSP (7). A total of 34 dif-
ferent genes were identified in the studies. Five studies evaluated the methylation status 
of a single gene [31,34,36,39,41] and 13 studies evaluated two or more genes [10–
12,30,32,33,35,37,38,40,42–44]. Ten studies focused on gene promoter methylation panels 
combining two to four genes, whereas eight studies evaluated only single genes. 
Table 1. Summary of descriptive characteristics of included studies. 
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of the included studies are show in Table 1. The 18 articles
comprised t tal of 84 study u its, i cluding 4758 HNC p tients and 3605 healthy in-
dividuals (the sampl size ranged from 13 [31] to 210 [41]). All articles wer published
between 2001 and 2020, and studies were conducted in the following geographical re-
gions: the United States (5), Australia (3), Thailand (2), Japan (2), France (1), Brazil (1),
India (1), Taiwan (1), Colombia (1), and Italy (1). Saliva samples included oral rinses
(12) and whole saliva (6). Salivary DNA methylation was detected by different methods,
including methylation-specific polymerase chain reaction (MSP) (11) and quantitative
MSP (7). A total of 34 different genes were identified in the studies. Five studies evalu-
ated the methylation status of a single gene [31,34,36,39,41] and 13 studies evaluated two
or more genes [10–12,30,32,33,35,37,38,40,42–44]. Ten studies focused on gene promoter
methylation panels combining two to four genes, whereas eight studies evaluated only
single genes.
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3.3. Quality Assessment of the Included Studies
All included articles were evaluated for risk of bias using the QUADAS-2 checklist
(Figure S1). The major risk of bias in this study was patient selection domain, as 13 out of
18 publications were unclear or lacked detail on whether the patient sample was consecutive
or random. Additionally, 14 out of 18 studies did not provide a detailed description of the
inclusion/exclusion criteria. Moreover, there was high risk of bias in the index test, since
some studies lacked a setting threshold. All domains were considered to have a low risk of
bias in terms of applicability concern. All studies were of moderate-to-high quality, with
an average QUADAS-2 score of 5.6.
3.4. Diagnostic Accuracy of Salivary DNA Promoter Hypermethylation
The diagnostic accuracy (sensitivity, specificity, and 95% confidence interval) of each
study unit (n = 74) included in this meta-analysis is shown in Figures 2 and 3. The pooled
sensitivity and specificity of salivary DNA hypermethylation genes in the diagnosis of
HNC were 0.39 (95% CI: 0.38–0.41) and 0.87 (95% CI: 0.86–0.88), respectively. The PLR
and NLR were 3.68 (95% CI: 2.97–4.57) and 0.63 (95% CI: 0.57–0.69) (Figures 4 and 5),
respectively; the summary dOR was 8.34 (95% CI: 6.10–11.39) (Figure S2); and the area
under the SROC was 0.81 (95% CI 0.77–0.84) (Figure 6). As shown in Fagan’s nomogram
(Figure S3), given a pre-test probability of 27.8%, a positive measurement leads to a post-test
cancer probability of 59%, whereas a negative measurement leads to a post-test probability
of 20%.
3.5. Heterogeneity and Subgroup Analysis
As shown in Figures 2–5 and Figure S2, significant heterogeneity was observed regard-
ing the pooled sensitivity (I2 = 96.33%; p < 0.001), specificity (I2 = 87.07%; p < 0.001), PLR
(I2 = 73.99%; p < 0.001), NLR (I2 = 96.35%; p < 0.001), and dOR (I2 = 71.83%; p < 0.001). The
representation of accuracy estimates from each study in the SROC space revealed a typical
pattern of a “shoulder arm”, suggesting the presence of a threshold effect (Figure S4).
Moreover, Spearman’s correlation coefficient between the logit of the true positive rate and
the logit of the false positive rate was 0.633 (p = 0.000), which showed further indication of
a threshold effect. In addition to the variations due to the threshold effect, meta-regression
was performed to determine the possible sources of heterogeneity using the following
covariates as predictor variables: sample type, sample size, anatomic tumor location, DNA
methylation methods, and methylation gene profiling. The results indicated that anatomic
tumor location (p = 0.002) and gene profiling (p < 0.001) were potential sources of hetero-
geneity in this study (Table S1). Consequently, subgroup analysis based on anatomic tumor
location (HNC vs. oral cancer vs. oropharyngeal cancer) and gene profiling (single vs.
combination of genes) was performed. As shown in Table S2, the results indicated similar
accuracy for salivary methylated genes in oral cancer (sensitivity, 0.63; specificity, 0.87;
PLR, 4.02; NLR, 0.40; dOR, 13.07; AUC, 0.88) and oropharyngeal cancer (sensitivity, 0.70;
specificity, 0.86; PLR, 3.67; NLR, 0.41; dOR, 13.26; AUC, 0.87). However, differences in
diagnostic accuracy were observed in the HNC group (sensitivity, 0.31; specificity, 0.86;
PLR, 3.03; NLR, 0.75; dOR, 5.78; AUC, 0.81). When basing the meta-analysis on gene profile,
the combination of methylated genes showed higher diagnostic accuracy (sensitivity, 0.73;
specificity, 0.88; PLR, 5.76; NLR, 0.22; dOR, 36.97; AUC, 0.92) compared to individual genes
(sensitivity, 0.32; specificity, 0.87; PLR, 3.17; NLR, 0.71; dOR, 6.02; AUC, 0.77). Although
the meta-regression results were negative for other covariates, we conducted subgroup
analyses based on these factors to further explore the diagnostic potential of salivary DNA
methylated genes (Table S2).
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3.6. Publication Bias
The potential publication bias in each salivary DNA methylation study was explored
by Deek ’ fun el plot asymmetry test, which yielded a slop coeffic ent p-value of 0.711
overall. T is indicatio of a s mmetric data pattern suggests the absence of publication
bias (Figure S5).
4. Discussion
Over th last few years, saliv has aroused great interes in the scientific community
du to its potential as a non-invasive liquid biopsy in cancer. Several studies have videnced
the diagnostic capability of salivary biomarkers for diagnosi g both HNC [45] and tumors
distant from the oral cavity [46]. In this sense, a wide variety f biomolecules have
been assessed as tumor biomarkers using saliva-omics approaches, including geno ic,
epigenomic, transcriptomic, etabolomic, proteomic, and microbiomic technologies [47].
In the field of epigeno ics, DNA promoter hypermethylation represents one of the most
intensively studied epigenetic alterations in human cancer. Promoter hypermethylation
of critical pathway genes has been recognized as an important epigenetic mechanism of
carcinogenesis [13]. Its potential role as an early diagnostic biomarker stems from the
fact that gene promoter hypermethylation is an early event in cancer development [13].
DNA hypermethylation as a common event in cancer plays an important role in HNC
development and progression [7]. The detection of DNA methylation in body fluids
has emerged as an opportunity to assess the methylation status non-invasively and cost-
effectively. In this line, several studies have investigated the promoter methylation of
different tumor-suppressor genes in saliva from HNC patients [10–12,38]. Therefore,
salivary DNA methylation biomarkers could be potentially used in the screening and early
detection of HNC.
To the best of our knowledge, this study represents the first meta-analysis evaluating
the diagnostic accuracy of promoter hypermethylation genes in saliva for differentiating
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HNC patients from healthy individuals. The present analysis included a total of 18 articles
(84 study units) involving 4758 HNC patients and 3605 healthy individuals. According to
QUADAS-2 quality evaluation, most of the included studies were of moderate quality. As
for the overall accuracy of salivary hypermethylated genes for discriminating HNC from
healthy individuals, the pooled diagnostic parameters of sensitivity, specificity, and AUC
values were 0.39, 0.87, and 0.81, respectively. The summary dOR of 8.34 reflects the diag-
nostic capacity of salivary hypermethylated genes for HNC. The pooled PLR value of 3.68
indicates that a person testing positive had approximately 3.68 times higher probability of
having cancer than a healthy individual. On the other hand, the pooled NLR indicated that
a person testing negative had a 63% probability of not having cancer. Additionally, given a
pre-test probability of 27.8% in Fagan’s nomogram, correct HNC diagnosis increased to
59% after a positive test, and reduced to 20% after a negative test. Overall, these results
show a low sensitivity for HNC detection, indicating a high false negative rate. Therefore,
the salivary gene methylation evaluated in this meta-analysis presented limitations as a
screening biomarker for HNC. However, the diagnostic specificity of gene methylation for
HNC was very high, suggesting that detection in saliva may aid assessment in HNC diag-
nosis. New molecular biology techniques such as next-generation sequencing platforms
and digital PCR represent an opportunity for improving the sensitivity of methylation
assays and for discovering new methylation patterns.
Due to the fact that heterogeneity is inherent to any diagnostic accuracy meta-analysis,
an evaluation of the reasons contributing to inconsistencies across studies should be carried
out. In the present research, overall heterogeneity among studies was high, so a bivariate
random effects model was applied. This significant heterogeneity was reflected numerically
in Cochran’s Q test and the I2 statistic. Further exploration of the heterogeneity revealed
the presence of a threshold effect. The threshold effect is a major source of heterogeneity in
meta-analyses of diagnostic tests. It arises from differences in sensitivities and specificities
or likelihood ratios due to different cut-offs among studies for defining positive (or negative)
test results [27]. In the present meta-analysis, the threshold effect was suggested by the
visual inspection of accuracy estimates in forest plots where increasing specificities with
decreasing sensitivities were observed. Later, the ROC plane and the Spearman correlation
test also indicated the presence of the threshold effect. The variations in accuracy estimates
among different studies could be due to a number of reasons other than the threshold, such
as study population (anatomic tumor location, TNM staging), index test (differences in
technology, assays), reference standard, and study design. Therefore, heterogeneity should
be explored by relating study level co-variates to an accuracy measure by meta-regression
techniques [27]. In the present study, meta-regression was performed to test the effect
of sample type, sample size, anatomic tumor location, DNA methylation method, and
methylated gene profiling. The results point to anatomic tumor location and gene profiling
strategy as possible causes of heterogeneity. Stratified analysis by anatomic tumor location
showed that salivary gene methylation had a higher diagnostic accuracy for discriminating
oral (AUC = 0.88) and oropharyngeal (AUC = 0.87) tumors than overall HNC (AUC = 0.81).
The explanation for these findings may be that tumors located in the oral cavity and
oropharynx release more tumor cells directly into saliva. With respect to gene profiling
strategy, subgroup analysis showed that single genes presented low sensitivity, but were
highly specific to cancer tissue. The combination of salivary methylated genes had better
diagnostic accuracy than single gene-based tests, with a dOR of 36.97 vs. 6.02 and AUC of
0.92 vs. 0.77, respectively, demonstrating that the use of salivary methylated gene panels as
biomarkers may increase HNC detection accuracy without decreasing specificity. We also
conducted subgroup analyses based on sample type, sample size, and DNA methylation
method but no significant differences in diagnostic accuracy were observed. Future studies
should be conducted to clarify the impact of these factors on the diagnostic potential of
salivary DNA methylation.
The current meta-analysis is not free of limitations. Firstly, this meta-analysis included
case–control studies, but none was multicenter. Moreover, no randomized controlled
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trials exist on this topic. Secondly, considerable heterogeneity was observed among the
included studies. Although we examined the sources of heterogeneity in five variables,
we were not able to explore other demographic and clinicopathological factors due to
lack of information. Thirdly, studies involving saliva samples only evaluated some of the
genes methylated in HNC tissue. The remaining genes should also be tested in saliva
to determine their diagnostic potential. Lastly, confounding variables such as gender,
age, lifestyle (tobacco and alcohol), and diet were not considered in most of the included
studies. Due to these limitations, future research based on large-scale prospective diagnostic
studies involving multiple health centers would contribute to further evaluating the clinical
utility of salivary gene promoter methylation for HNC diagnosis. Furthermore, better
comparison among future studies would benefit from standardization of analytic strategies
and cut-off selection.
5. Conclusions
Our meta-analysis suggests that the detection of DNA promoter hypermethylation
in saliva is a promising biomarker for HNC diagnosis, mainly in oral and oropharyngeal
tumors. The use of salivary hypermethylated gene panels improves diagnostic accuracy
with respect to single-gene analysis. This meta-analysis could provide valuable insights
into methodology design for further research studies.
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